AC Immune SA
Building B
EPFL Innovation Park
Lausanne 1015
Switzerland
41 21 345 91 21
https://www.acimmune.com
版塊: Healthcare
行業: Biotechnology
全職員工: 133
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Andrea Pfeifer Ph.D. | Co-Founder, CEO & Director | 1.1M | 無 | 1957 |
| Mr. Christopher Roberts | CFO & VP of Finance | 無 | 無 | 1990 |
| Mr. Piergiorgio Donati | Chief Technical Operations Officer | 無 | 無 | 1971 |
| Mr. Jean-Fabien Monin | Chief Administrative Officer | 無 | 無 | 1971 |
| Mr. Howard Donovan | Chief HR Officer | 無 | 無 | 1976 |
| Ms. Madiha Derouazi | Chief Scientific Officer | 無 | 無 | 1973 |
| Dr. Gary Anthony Waanders Ph.D. | Senior VP of Investor Relations & Corporate Communications | 無 | 無 | 1964 |
| Mr. Alexandre Caratsch | General Counsel | 無 | 無 | 1966 |
| Mr. Julian Snow | VP of U.S. Finance & Corporate Development | 無 | 無 | 無 |
| Dr. David T. Hickman | Head of AD - SME | 無 | 無 | 無 |
描述
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It is developing Crenezumab, a humanized, conformation-specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome-related AD; ACI-7104.056, to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it is developing diagnostic programs, consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD and NeuroOrphan Tauopathies. Additionally, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
公司管治
截至 無 止，AC Immune SA 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
